The coronavirus global pandemic has ushered in extraordinary roadblocks for the pharmaceutical industry. To help you carve out a path forward, in-house senior executives and industry leaders will convene virtually at ACI’s complimentary webinar “Examining the COVID-19 Effect on the Business and Practice of Hatch-Waxman Litigation” on Tuesday, June 2 | 12:00 – 1:00 PM EST to help you navigate FDA approval schedules, filing deadlines and launch dates during these unprecedented times.

Join the discussion with the leading practitioners and litigators:

Topics of discussion will include:

• Understanding the potential long-term impact the coronavirus could have on supply chain disruption

• Evaluating the impact of the conservation of resources on future investment in research and development

• Reconciling court docket delays and Hatch-Waxman Act 30-month stays

• Assessing the role of governmental intervention with respect to extensions

• Identifying methods for overcoming mounting delays to pharmaceutical patent litigation caused by the coronavirus

• Analyzing the impact of the coronavirus on deadlines before the USPTO and PTAB

With so much on the line, we’re evolving to help you address critical, high stakes developments impacting your organization’s path forward. Until we gather in person at the 14th Annual Paragraph IV Disputes in August, nothing stops connection and innovation. Register to this complimentary webinar today!

Click here to see the details »